While Barbie’s career options have increased, there is clearly still room for improvement
In her elegant qualitative study, Katherine Klamer dares the reader to dream bigger for a rising generation of girls.1 In an analysis of nearly 90 Barbies, Klamer found that Barbie brand medical professional dolls largely treated children (63%, n=48/76), with only three dolls (4%, n=3/76) working with adults. 59% of the Barbie brand dolls were white, 28% black, and 6% East Asian, and none had any physical disabilities. All Barbie brand doctors appeared to have either no specialization or were paediatricians with no apparent sub-specialization. Analysis showed that the dolls’ personal safety accessories were inadequate for standard practice; 98% of the Barbie brand dolls came with stethoscopes yet only 4% had face masks. Overall, the group of Barbies showed only a very limited range of medical careers.1 As surgeons in decidedly male dominated fields, we support Klamer’s conclusion that Barbi
As first conceptualized in 1959 by American businesswoman Ruth Marianna Handler, the iconic Barbie doll has been a source of inspiration for generations of women.
Barbie Urged to Broaden Medical, Scientific Career Range miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
BOSTON - New research led by a team at Massachusetts General Hospital (MGH) points to a promising strategy to boost tumors intake of cancer drugs, thereby increasing the effectiveness of chemotherapy treatments. The group s findings are published in
Getting enough anticancer drugs into a tumor is often difficult, and a potential strategy to overcome this challenge involves binding the medications to albumin, the most abundant protein in blood. The strategy relies on tumors large appetite for protein nutrients that fuel malignant growth. When consuming available albumin, the tumors will inadvertently take in the attached drugs.
A popular albumin-bound drug approved by the U.S. Food and Drug Administration is nanoparticle albumin-bound paclitaxel (nab-PTX), and it has been successfully used to treat late-stage lung and pancreatic cancers. Not all patients respond to nab-PTX, though, and the effectiveness of its delivery to tumors has been mixed, owing to an incomplete u